Uday R Popat

78PUBLICATIONS
411CO-AUTHORS
Molecular targetsHaematological tumoursRegenerative medicine (incl. stem cells)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (78)

|Sep 24, 2026
Phase 1, open-label, multicenter study of sovleplenib (HMPL-523) in patients with relapsed or refractory lymphoma.

|Aug 20, 2026
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma.

|Jul 31, 2026
Phase I/II Trial of Evomela for Autologous Transplant in Myeloma: Schedule Optimization and Matched Comparison with MEL200.

|Jul 29, 2026
Impact of EBV Status and Histology on Patient Outcomes with Nivolumab-AVD vs BV-AVD in Advanced Classic Hodgkin Lymphoma (S1826).

|Jul 16, 2026
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

|Jul 08, 2026
Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Pageof 13

Frequent Collaborators

16 joint publications

Sattva S Neelapu

14 joint publications

Jason Westin

13 joint publications

Mehdi Hamadani

11 joint publications

Raphael Steiner